197 related articles for article (PubMed ID: 18423896)
1. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.
Wang S; Fischer PM
Trends Pharmacol Sci; 2008 Jun; 29(6):302-13. PubMed ID: 18423896
[TBL] [Abstract][Full Text] [Related]
2. Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
Krystof V; Baumli S; Fürst R
Curr Pharm Des; 2012; 18(20):2883-90. PubMed ID: 22571657
[TBL] [Abstract][Full Text] [Related]
3. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological targeting of CDK9 in cardiac hypertrophy.
Krystof V; Chamrád I; Jorda R; Kohoutek J
Med Res Rev; 2010 Jul; 30(4):646-66. PubMed ID: 19757441
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.
Németh G; Greff Z; Sipos A; Varga Z; Székely R; Sebestyén M; Jászay Z; Béni S; Nemes Z; Pirat JL; Volle JN; Virieux D; Gyuris Á; Kelemenics K; Ay E; Minarovits J; Szathmary S; Kéri G; Orfi L
J Med Chem; 2014 May; 57(10):3939-65. PubMed ID: 24742150
[TBL] [Abstract][Full Text] [Related]
6. Novel, selective CDK9 inhibitors for the treatment of HIV infection.
Németh G; Varga Z; Greff Z; Bencze G; Sipos A; Szántai-Kis C; Baska F; Gyuris A; Kelemenics K; Szathmáry Z; Minárovits J; Kéri G; Orfi L
Curr Med Chem; 2011; 18(3):342-58. PubMed ID: 21143121
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
8. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis.
Iankova I; Petersen RK; Annicotte JS; Chavey C; Hansen JB; Kratchmarova I; Sarruf D; Benkirane M; Kristiansen K; Fajas L
Mol Endocrinol; 2006 Jul; 20(7):1494-505. PubMed ID: 16484339
[TBL] [Abstract][Full Text] [Related]
10. Halogen bonds form the basis for selective P-TEFb inhibition by DRB.
Baumli S; Endicott JA; Johnson LN
Chem Biol; 2010 Sep; 17(9):931-6. PubMed ID: 20851342
[TBL] [Abstract][Full Text] [Related]
11. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
[TBL] [Abstract][Full Text] [Related]
12. Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy.
Karati D; Mahadik KSR; Trivedi P; Kumar D
Anticancer Agents Med Chem; 2023; 23(4):383-403. PubMed ID: 35708082
[TBL] [Abstract][Full Text] [Related]
13. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 9 forms a complex with GATA4 and is involved in the differentiation of mouse ES cells into cardiomyocytes.
Kaichi S; Takaya T; Morimoto T; Sunagawa Y; Kawamura T; Ono K; Shimatsu A; Baba S; Heike T; Nakahata T; Hasegawa K
J Cell Physiol; 2011 Jan; 226(1):248-54. PubMed ID: 20665673
[TBL] [Abstract][Full Text] [Related]
15. Targeting CDK9: a promising therapeutic opportunity in prostate cancer.
Rahaman MH; Kumarasiri M; Mekonnen LB; Yu M; Diab S; Albrecht H; Milne RW; Wang S
Endocr Relat Cancer; 2016 Dec; 23(12):T211-T226. PubMed ID: 27582311
[TBL] [Abstract][Full Text] [Related]
16. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Hole AJ; Baumli S; Shao H; Shi S; Huang S; Pepper C; Fischer PM; Wang S; Endicott JA; Noble ME
J Med Chem; 2013 Feb; 56(3):660-70. PubMed ID: 23252711
[TBL] [Abstract][Full Text] [Related]
17. Overview of CDK9 as a target in cancer research.
Morales F; Giordano A
Cell Cycle; 2016; 15(4):519-27. PubMed ID: 26766294
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
[TBL] [Abstract][Full Text] [Related]
19. CDK9 as an Appealing Target for Therapeutic Interventions.
Eyvazi S; Hejazi MS; Kahroba H; Abasi M; Zamiri RE; Tarhriz V
Curr Drug Targets; 2019; 20(4):453-464. PubMed ID: 30362418
[TBL] [Abstract][Full Text] [Related]
20. Computer-aided design, synthesis and validation of 2-phenylquinazolinone fragments as CDK9 inhibitors with anti-HIV-1 Tat-mediated transcription activity.
Sancineto L; Iraci N; Massari S; Attanasio V; Corazza G; Barreca ML; Sabatini S; Manfroni G; Avanzi NR; Cecchetti V; Pannecouque C; Marcello A; Tabarrini O
ChemMedChem; 2013 Dec; 8(12):1941-53. PubMed ID: 24150998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
